Cardinal Health (NYSE:CAH - Get Free Report) had its price target upped by equities research analysts at Wells Fargo & Company from $277.00 to $321.00 in a report issued on Tuesday, Benzinga reports. The firm currently has an "overweight" rating on the stock. Wells Fargo & Company's price target would indicate a potential upside of 13.05% from the company's current price.
Several other equities research analysts have also commented on the stock. Mizuho set a $290.00 price objective on shares of Cardinal Health in a research report on Thursday, November 5th. Royal Bank Of Canada boosted their price target on Cardinal Health from $276.00 to $295.00 and gave the stock an "outperform" rating in a report on Friday, November 6th. Robert W. Baird increased their price objective on Cardinal Health from $251.00 to $274.00 and gave the company an "outperform" rating in a research note on Wednesday, August 12th. Leerink Partners set a $292.00 price objective on Cardinal Health in a research report on Tuesday, August 11th. Finally, Morgan Stanley boosted their target price on shares of Cardinal Health from $265.00 to $286.00 and gave the company an "overweight" rating in a research note on Friday, October 30th. One research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $282.19.
Check Out Our Latest Analysis on Cardinal Health
Cardinal Health Price Performance
NYSE:CAH opened at $283.95 on Tuesday. The firm's fifty day moving average price is $244.90 and its 200 day moving average price is $225.61. Cardinal Health has a 1-year low of $180.45 and a 1-year high of $286.29. The firm has a market cap of $65.63 billion, a price-to-earnings ratio of 36.73, a price-to-earnings-growth ratio of 2.13 and a beta of 0.53.
Cardinal Health (NYSE:CAH - Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The company reported $3.26 EPS for the quarter, topping analysts' consensus estimates of $2.94 by $0.32. Cardinal Health had a net margin of 0.71% and a negative return on equity of 102.72%. The company had revenue of $67.51 billion during the quarter, compared to the consensus estimate of $66.67 billion. During the same quarter in the prior year, the firm earned $2.55 EPS. Cardinal Health's quarterly revenue was up 5.5% on a year-over-year basis. As a group, analysts expect that Cardinal Health will post 12.97 earnings per share for the current fiscal year.
Insider Buying and Selling at Cardinal Health
In related news, CEO Jason M. Hollar sold 44,529 shares of the stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $236.18, for a total value of $10,516,859.22. Following the completion of the transaction, the chief executive officer owned 190,603 shares of the company's stock, valued at approximately $45,016,616.54. This represents a 18.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CAO Mary C. Scherer sold 2,302 shares of Cardinal Health stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $237.39, for a total value of $546,471.78. Following the sale, the chief accounting officer owned 2,811 shares in the company, valued at $667,303.29. This represents a 45.02% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 0.12% of the company's stock.
Institutional Inflows and Outflows
A number of large investors have recently bought and sold shares of the company. Pinnacle Associates Ltd. raised its holdings in shares of Cardinal Health by 2.9% during the third quarter. Pinnacle Associates Ltd. now owns 1,404 shares of the company's stock worth $312,000 after purchasing an additional 39 shares during the period. Composition Wealth LLC grew its holdings in shares of Cardinal Health by 1.7% during the third quarter. Composition Wealth LLC now owns 2,383 shares of the company's stock valued at $530,000 after purchasing an additional 39 shares during the last quarter. Parallel Advisors LLC lifted its holdings in shares of Cardinal Health by 1.4% in the 3rd quarter. Parallel Advisors LLC now owns 3,004 shares of the company's stock worth $668,000 after purchasing an additional 41 shares during the last quarter. LWM Advisors Inc. grew its stake in Cardinal Health by 4.4% during the 2nd quarter. LWM Advisors Inc. now owns 1,028 shares of the company's stock worth $244,000 after buying an additional 43 shares during the last quarter. Finally, Parkside Financial Bank & Trust lifted its stake in Cardinal Health by 2.5% in the second quarter. Parkside Financial Bank & Trust now owns 1,793 shares of the company's stock valued at $426,000 after buying an additional 43 shares during the last quarter. Institutional investors own 87.17% of the company's stock.
About Cardinal Health
(
Get Free Report)
Cardinal Health is a healthcare services and products company that distributes pharmaceuticals and medical supplies. Its customers include pharmacies, hospitals, surgery centers, physician offices and other healthcare providers. The company's businesses include pharmaceutical distribution and specialty services, as well as the sourcing and distribution of medical and surgical products. Its offerings support areas such as specialty medications, medication management and supply-chain operations. Cardinal Health traces its roots to a wholesale business founded in Ohio in 1971 and later expanded into pharmaceutical distribution.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cardinal Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardinal Health wasn't on the list.
While Cardinal Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.